-
Dr. Jin Yang: Advances in Endocrine Therapy for Early Breast Cancer – Precision Medicine Opportunities and Challenges
Oncology Frontier: Could you briefly summarize the important advances in endocrine therapy for early breast cancer in 2024? Dr. Jin Yang: Overall, the progress in endocrine therapy for HR+/HER2- early…
-
Annual Review | Dr. Changli Wang: Advances and Future Perspectives in Perioperative Immunotherapy for NSCLC in 2024
In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens,…
-
Annual Review | Dr. Yongmei Yin: Advances in HER2-Positive Breast Cancer Research in 2024
As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year’s advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.
-
Dr. Yan Wang Discusses Advances in Research on Rare Mutations in NSCLC in 2024 | 2024 Academic Conference on Precision Diagnosis and Treatment of Lung
Oncology Frontier: With the progress in the precise diagnosis of lung cancer, many rare/rare gene mutations have been discovered. First, could you briefly introduce the current hottest rare targets? Dr.…
-
Gut | Aspirin Use Lowers Pancreatic Cancer Risk and Mortality in Type 2 Diabetes Patients
Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery…
-
Insights from Medical Experts – Launch of the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines
At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the “New Little Red Book”) was officially released during the 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee. This updated edition provides fresh guidance for…
-
Dr. Yan Huang: Advances in Perioperative Drug Therapy for NSCLC | 2024 Academic Conference on Precision Diagnosis and Treatment of Lung Cancer
Oncology Frontier: Perioperative treatment for early-stage non-small cell lung cancer (NSCLC) has entered the era of targeted and immunotherapy. What breakthroughs in perioperative targeted therapy were seen in 2024? Dr.…
-
Annual Review | Dr. Ai Li Suo: Advances and Reflections on Targeted Therapy for Gastric Cancer in 2024
In recent years, as research has deepened, the exploration of gastric cancer’s molecular mechanisms has gradually shifted from histological classification to molecular classification. Different biomarkers have profoundly influenced the treatment landscape of advanced gastric cancer in first-line and subsequent therapies. At the close of this year, Oncology Frontier is honored to invite Dr. Ai Li…
Connecting Medical Expertise through Media